Jacobs Levy Equity Management
TARS icon

Jacobs Levy Equity Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Jacobs Levy Equity Management’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-41,667
Closed -$753K – 1060
2023
Q2 		$753K Buy
+41,667
New +$662K ﹤0.01% 748
2022
Q4 		– Sell
-86,948
Closed -$1.49M – 1035
2022
Q3 		$1.49M Buy
86,948
+4,906
+6% +$77.9K 0.01% 619
2022
Q2 		$1.2M Buy
+82,042
New +$1.23M 0.01% 715

Other funds holding TARS

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Jacobs Levy Equity Management's TARS Position: Q3 2023 in Review

Jacobs Levy Equity Management sold out of Tarsus Pharmaceuticals (TARS) in Q3 2023, closing a stake of 41,667 shares — an estimated $753K sold.

Jacobs Levy Equity Management first reported a position in TARS in Q2 2022 and held it in 3 quarters. The position peaked at $1.49M in Q3 2022. 105 funds tracked by Wall St. Rank hold TARS as of Q3 2023.

  • Jacobs Levy Equity Management reported no remaining Tarsus Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 41,667 Tarsus Pharmaceuticals shares in Q3 2023, an estimated $753K.
  • Jacobs Levy Equity Management first reported a position in Tarsus Pharmaceuticals in Q2 2022 and held it in 3 quarters.
  • Jacobs Levy Equity Management's Tarsus Pharmaceuticals position peaked at $1.49M in Q3 2022.
  • 105 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q3 2023.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2023, filed 17 Nov 2023.